Clearmind Medicine Inc (CMND) Actualités

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

The term sheet is non-binding, subject to the execution of a definitive agreement  Vancouver, Canada, Dec. 16...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]